AR126414A1 - Método de producción de la composición de inhibidores de ciclooxigenasa-2 (cox-2) - Google Patents
Método de producción de la composición de inhibidores de ciclooxigenasa-2 (cox-2)Info
- Publication number
- AR126414A1 AR126414A1 ARP220101797A ARP220101797A AR126414A1 AR 126414 A1 AR126414 A1 AR 126414A1 AR P220101797 A ARP220101797 A AR P220101797A AR P220101797 A ARP220101797 A AR P220101797A AR 126414 A1 AR126414 A1 AR 126414A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- cyclooxygenase
- cox
- inhibitors
- production method
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000010907 Cyclooxygenase 2 Human genes 0.000 title abstract 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000005323 carbonate salts Chemical class 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
Abstract
La divulgación está dirigida al método de producción de la composición de un inhibidor de la ciclooxigenasa- 2 (COX-2) que comprende un excipiente soluble en agua que comprende HPMC y un ácido orgánico y otro u otros componentes. La composición puede presentarse en la forma de pellets, un comprimido, una cápsula o gránulos, con mayor disolución de API o rápida desintegración en el medio acuoso. En algunas formas de realización, la composición contiene además una sal de carbonato para formar una formulación de desintegración débilmente efervescente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021902100A AU2021902100A0 (en) | 2021-07-09 | Weakly Effervescent Disintegrating Formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
AR126414A1 true AR126414A1 (es) | 2023-10-11 |
Family
ID=84801500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220101797A AR126414A1 (es) | 2021-07-09 | 2022-07-08 | Método de producción de la composición de inhibidores de ciclooxigenasa-2 (cox-2) |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4366732A1 (es) |
KR (1) | KR20240035509A (es) |
CN (1) | CN117813089A (es) |
AR (1) | AR126414A1 (es) |
AU (1) | AU2022305851A1 (es) |
CA (1) | CA3220327A1 (es) |
IL (1) | IL310054A (es) |
TW (1) | TW202320761A (es) |
WO (1) | WO2023281449A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2823668B1 (fr) * | 2001-04-20 | 2004-02-27 | Ethypharm Lab Prod Ethiques | Comprimes effervescents orodispersibles |
EP1833476A1 (en) * | 2004-11-23 | 2007-09-19 | PLIVA HRVATSKA d.o.o. | Extended release pharmaceutical composition of celecoxib |
WO2006079923A2 (en) * | 2005-01-31 | 2006-08-03 | Pharmacia & Upjohn Company Llc | Form iv crystalline celecoxib |
CN101002741A (zh) * | 2005-09-26 | 2007-07-25 | 刘凤鸣 | 塞来昔布的缓释制剂 |
KR101237646B1 (ko) * | 2010-12-09 | 2013-03-04 | 주식회사 드림파마 | 생체이용률이 개선된 셀레콕시브 함유 고체 분산체, 이를 포함하는 약학 조성물 및 이의 제조방법 |
CN105343030A (zh) * | 2015-12-16 | 2016-02-24 | 钟柏根 | 一种塞来昔布胶囊及其制备方法 |
CN107115313A (zh) * | 2017-07-03 | 2017-09-01 | 福建省福抗药业股份有限公司 | 一种塞来昔布组合物及其制备方法 |
-
2022
- 2022-07-08 AR ARP220101797A patent/AR126414A1/es unknown
- 2022-07-08 TW TW111124075A patent/TW202320761A/zh unknown
- 2022-07-08 IL IL310054A patent/IL310054A/en unknown
- 2022-07-08 CN CN202280035972.7A patent/CN117813089A/zh active Pending
- 2022-07-08 EP EP22837146.4A patent/EP4366732A1/en active Pending
- 2022-07-08 KR KR1020247004069A patent/KR20240035509A/ko unknown
- 2022-07-08 AU AU2022305851A patent/AU2022305851A1/en active Pending
- 2022-07-08 WO PCT/IB2022/056309 patent/WO2023281449A1/en active Application Filing
- 2022-07-08 CA CA3220327A patent/CA3220327A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2023281449A1 (en) | 2023-01-12 |
CN117813089A (zh) | 2024-04-02 |
KR20240035509A (ko) | 2024-03-15 |
IL310054A (en) | 2024-03-01 |
CA3220327A1 (en) | 2023-01-12 |
EP4366732A1 (en) | 2024-05-15 |
TW202320761A (zh) | 2023-06-01 |
AU2022305851A1 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP18091468A (es) | Complejos radio-farmacéuticos | |
TR201909173T4 (tr) | İşlevselleştirilmiş kalsiyum karbonat içeren hızlı parçalanan katı dozaj formundaki formülasyon ve bunun üretim yöntemi. | |
MX2015013244A (es) | Pelicula soluble formadora de gel para suministrar agentes activos. | |
IN2012DN03447A (es) | ||
CR10349A (es) | Tabletas de paracetamol de liberacion rapida | |
AR052225A1 (es) | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones | |
CL2012002115A1 (es) | Una pastilla blanda que comprende nicotina, gelificante, platificante, edulcorante, agente liberador, conservante, saborizante, agua y es capaz de disolverse en la cavidad bucal en un periodo de 5 y 15 minutos; y proceso de preparacion. | |
AR074347A1 (es) | Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso | |
ECSP20009533A (es) | Preparación que comprende vonoprazán | |
PE20181177A1 (es) | Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas | |
CL2008001966A1 (es) | Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques. | |
AR096806A1 (es) | Mejora de la conductividad de redes complejas de fracturación en formaciones subterráneas | |
PE20061338A1 (es) | Combinacion de antagonistas del receptor adrenergico alfa 1 o inhibidores de 5 alfa reductasa con inhibidores de pde 5 para la terapia de hiperplasia benigna de prostata | |
UY32624A (es) | Procedimiento y composición para mejorar la absorción de agentes terapéuticos | |
ECSP10010514A (es) | Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente | |
AR126414A1 (es) | Método de producción de la composición de inhibidores de ciclooxigenasa-2 (cox-2) | |
AR051654A1 (es) | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones | |
AR074739A1 (es) | Comprimidos de capecitabina de disgregacion rapida | |
MX2019015733A (es) | Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva. | |
CY1122387T1 (el) | Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων | |
UY38301A (es) | Cannabidiol soluble en agua | |
TR2023019031T2 (tr) | Siklooksijenaz-2 (cox-2) inhibitörleri bileşiminin üretim yöntemi. | |
BR112019006643A2 (pt) | nanopartículas de ouro encapsuladas em mangiferina e métodos de fabricação e terapêuticos contra o câncer | |
NZ605562A (en) | Deuterated benzylbenzene derivatives and methods of use | |
UY29728A1 (es) | Forma farmacéutica con liberación sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph. |